Lipid-Lowering Therapy for Statin-Intolerant Patients with Ischemic Heart Disease

Introduction to Statin-Intolerant Patient Management

The European Society of Cardiology recommends ezetimibe as first-line therapy for statin-intolerant patients with ischemic heart disease, with a Class I recommendation and Level B evidence 1
Ezetimibe provides a 15-25% reduction in LDL-C as monotherapy 2
The European Society of Cardiology guidelines recommend ezetimibe as first-line therapy in cases of intolerance to any statin regimen, with a Class I recommendation and Level B evidence 1

For patients who are statin intolerant and do not achieve their goal on ezetimibe, combination with bempedoic acid is recommended, with a Class I recommendation and Level B evidence 1
If LDL-C goals remain unmet on ezetimibe ± bempedoic acid, adding a PCSK9 inhibitor (alirocumab or evolocumab) is recommended 1
PCSK9 inhibitors reduce LDL-C by approximately 60% when added to other therapies 1
PCSK9 inhibitors significantly reduce non-fatal cardiovascular events in secondary prevention 1

The target LDL-C goal for a 45-year-old patient with established ischemic heart disease is <1.4 mmol/L (55 mg/dL) with ≥50% reduction from baseline, with a Class I recommendation and Level A evidence 1
If a second vascular event occurs within 2 years, consider an even lower target of <1.0 mmol/L (40 mg/dL) 1

All patients require intensive lifestyle modification, including exercise, diet, and weight control, which favorably affect lipid levels 1
These interventions are recommended for all patients with chronic coronary syndrome 1

The European Society of Cardiology guidelines state that fibrates may be considered in statin-intolerant patients, particularly when triglycerides are elevated or HDL is low (Class IIa, Level B) 3

Fenofibrate should only be considered as adjunctive therapy if a patient has persistent hypertriglyceridemia (>150 mg/dL) or low HDL cholesterol (<40 mg/dL) after ezetimibe initiation 3
The American Heart Association/American Stroke Association guidelines note that nonstatin therapies including fibrates have unestablished efficacy for stroke prevention (Class IIb, Level C) 4

For a patient with ischemic heart disease, LDL-C reduction is the priority for mortality and morbidity reduction, not triglyceride management 3, 5

Implement intensive lifestyle modifications including a Mediterranean diet, regular aerobic exercise, and weight management 3, 5

Do not use fenofibrate as a direct statin replacement for LDL-C lowering in secondary prevention, as it does not adequately address the primary therapeutic target (LDL-C) in patients with established ischemic heart disease 3, 4